Discover open access scientific publications

Search, annotate, share and cite publications

Publications by MerriKay Oleen-Burkey

Examining the Influence of Behavioral Factors on Compliance and Persistence With Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

Journal of Neurology & Neurophysiology

2014

English

Related publications

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

English

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

English

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

English

Sub-Analysis of Geographical Variations in the 2-Year Observational COPTIMIZE Trial of Patients With Relapsing–remitting Multiple Sclerosis Converting to Glatiramer Acetate

English

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

English

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Archives of Neurology

2009

English

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Arquivos de Neuro-Psiquiatria

Biological Psychiatry

Neurology

1999

English

Modelling the Impact of Persistence Improvements With an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by MerriKay Oleen-Burkey

Examining the Influence of Behavioral Factors on Compliance and Persistence With Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

Related publications

Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

Sub-Analysis of Geographical Variations in the 2-Year Observational COPTIMIZE Trial of Patients With Relapsing–remitting Multiple Sclerosis Converting to Glatiramer Acetate

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis

Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis

Cognitive Profile of Patients With Relapsing Remitting Multiple Sclerosis

Modelling the Impact of Persistence Improvements With an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)